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Sarcomas were one of the first solid cancers to be linked to ionizing radiation exposure. We reviewed the current
evidence on this relationship, focusing particularly on the studies that had individual estimates of radiation doses.
There is clear evidence of an increased risk of both bone and soft tissue sarcomas after high-dose fractionated
radiation exposure (10 +Gy) in childhood, and the risk increases approximately linearly in dose, at least up to 40 Gy.
There are few studies available of sarcoma after radiotherapy in adulthood for cancer, but data from cancer
registries and studies of treatment for benign conditions confirm that the risk of sarcoma is also increased in this
age-group after fractionated high-dose exposure. New findings from the long-term follow-up of the Japanese
atomic bomb survivors suggest, for the first time, that sarcomas can be induced by acute lower-doses of radiation
(<5 Gy) at any age, and the magnitude of the risk is similar to that observed for other solid cancers. While there is
evidence that individuals with certain rare familial genetic syndromes predisposing to sarcoma, particularly
Nijmegen Breakage Syndrome, are particularly sensitive to the effects of high dose radiation, it is unclear whether
this is also true in very low-dose settings (<0.1 Gy). The effects of common low-penetrance alleles on
radiosensitivity in the general population have not been well-characterized. Some evidence suggests that it may be
possible to identify radiation-induced sarcomas by a distinct molecular signature, but this work needs to be
replicated in several dose settings, and the potential role of chemotherapy and tumor heterogeneity needs to be
examined in more detail. In summary, radiation exposure remains one of the few established risk factors for both
bone and soft tissue sarcomas. Similar to many other cancers children have the highest risks of developing a
radiation-related sarcoma. Efforts to limit unnecessary high-dose radiation exposure, particularly in children,
therefore remain important given the high fatality rates associated with this disease.Sarcomas are a rare but highly fatal outcome of radiation
exposure. The first case reports of bone sarcomas in
patients who had received radiotherapy for benign bone
conditions were published as early as 1922 [1], making it
one of the first solid cancers to be linked to radiation.
Martland’s famous report of bone sarcomas in the jaws of
radium-dial painters followed in 1929 [2]. In the last few
decades much has been learned about the relationship by
studying the occurrence of sarcomas after radiotherapy
treatment for both benign and malignant diseases. Never-
theless, because radiation-related sarcoma is a very rare
event, studies have generally been small, and many ques-
tions remain about the relationship. Uncertainties include
the shape of the dose–response relationship, particularly
at lower (<5 Gy (Gray)) and very high absorbed doses
(20 +Gy), the impact of factors such as age at exposure,
time since exposure, sex and genetic susceptibility on risk* Correspondence: berringtona@mail.nih.gov
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distribution, and reproduction in any mediumas well as understanding variation in risk by sarcoma sub-
type. Attempts to find a radiation-signature are also cur-
rently underway and sarcomas are one of the cancers that
have been targeted for these studies.
In this article we review the epidemiological evidence on
the association between radiation exposure and develop-
ment of sarcoma, including both bone and connective tis-
sue sarcomas but differentiating where possible. We focus
on studies of radiotherapy for malignant conditions, espe-
cially those with individual estimates of absorbed radiation
dose to the site of the sarcoma (unless otherwise specified
this is the dose that we refer to throughout the article).
Treatment of benign conditions has mostly been discon-
tinued and little new data are available since previous
reviews [3]. However, we briefly review the findings from
these studies and other non-medical populations, espe-
cially where there are gaps in the evidence from the stud-
ies of treatment for malignant disease. We include
assessment of potential effect modifiers including geneticBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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potential radiation-signatures for this disease.
High dose radiation exposure (5 + Gy)
We searched PUBMED using search terms including
sarcoma, radiotherapy, dose and subsequent malignancy,
and also reviewed the references of included articles. We
identified nine studies of radiotherapy treatment and risk
of subsequent sarcoma that had estimated the absorbed
radiation dose to the site of the sarcoma for each patient
[4-11] (Table 1). Six of the studies were of childhood
cancers (five included a variety of first cancers and one
focused on retinoblastoma); the three studies of adult-
hood cancer included two studies of cervical cancer and
one study of breast cancer survivors. In total these stud-
ies included 332 cases of sarcoma and the average dose
in the controls varied from 5–27 Gray (Gy). We describe
the results below according to age at exposure (child-
hood versus adulthood) and outcome (bone, soft tissue
or both).
Childhood radiotherapy
There were three studies of bone sarcoma after childhood
cancer [4-6]. All three studies found that the risk of bone
sarcoma increased with increasing radiation dose
(Figure 1a). In two of the studies there was evidence that
the risk declined after very high doses (40+Gy) [5,6],
which could be the result of high levels of cell killing. ForTable 1 Characteristics of the nine case–control studies of sub
with individual dose estimates
Reference 2nd cancer 1st cancer Cases
Radiotherapy in Childhood
Tucker 1987 [4] Bone Sarcoma Childhood 68
Hawkins 1996 [5] Bone Sarcoma Childhood 50
Le Vu 1998 [6] Osteosarcoma Childhood 32
Wong 1997 [7] Soft tissue
sarcoma
Retinoblastoma 31
Menu-Branthomme 2004 [8] Soft tissue
sarcoma
Childhood 23




Boice 1988 [10] Bone Sarcoma Cervix 15
Boice 1988 [10] Soft tissue
sarcoma
Cervix 46
Rubino 2005 [11] All sarcomas Breast 14
na – not available. ERR/Gy – excess relative risk per Gray. * UNSCEAR [12].around 20 Gy the relative risk varied from 6 [4] to 24 [6]
compared to zero or very low doses of radiation, and in
two of the three studies there was little evidence of an
excess risk for exposures below 10 Gy, but this could be a
result of low statistical power rather than real evidence in
support of a threshold (see below for additional comment
on lower-dose studies). All three studies included patients
with retinoblastoma and these patients are discussed in
more detail below as there is evidence of an underlying
increased risk of sarcoma in these patients, possibly due to
genetic factors.
Of the three studies that examined soft tissue sarcoma in
relation to radiation dose from radiotherapy treatment
[7-9] one consisted only of patients with retinoblastoma
[7]. All three studies found an approximately linear rela-
tionship between dose and risk, although the magnitude of
the relative risk was somewhat lower though than that
reported for bone sarcomas (Figure 1b). For a dose of about
20 Gy the relative risk for soft tissue sarcoma was variable:
3 (0.6-14.6) in Menu-Branthomme et al [8], 4.6 (1.7-24.8)
in Wong et al. [7], and 37.1 (4.5-309.3) in Jenkinson et al.
[9], but the confidence intervals were wide and overlapping.
Again there was little evidence of increased risks for doses
below 10 Gy, possibly due to low statistical power.
Five of the six studies of childhood radiotherapy
assessed the potential interaction between radiotherapy
and chemotherapy [4-6,8,9], and four [4-6,8] of these




Controls 1st cancer Sarcoma Average Max (& 95% Cl)
209 7 yrs na 27 Gy 60+ Gy 0.06
(0.01–0.20)*
168 ns na 5 Gy 50+ Gy 0.16
(0.07–0.37)*
160 6 yrs 15 yrs 8 Gy 83 Gy 1.4 (0.1–21.8)
89 <2 yrs 15 yrs 11 Gy 112 Gy 0.17
(0.025–16.3)
111 8 yrs 21 yrs 12 Gy 50 Gy na
179 7 yrs 17 yrs 5 Gy 30+ Gy na
155 50 yrs 67 yrs 22 Gy 10+ Gy 0.02
(−0.03–0.21)*
598 50 yrs 67 yrs 7 Gy 10+ Gy −0.05
(−0.11–0.13)*
98 55 yrs 62 yrs 19 Gy 80 Gy 0.05 (<0-1.18)
Figure 1 Relative risk of sarcoma according to radiation dose
(Gy) after radiotherapy for childhood cancer. a) Bone sarcoma.
b) Soft tissue sarcoma.
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with respect to subsequent risk of sarcoma. Whilst this
is consistent with no interaction, from the statistical per-
spective, it still means that those patients who received
both treatmenta often had a very high risk of developing
a subsequent sarcoma. In the remaining study [9] theTable 2 Standardized Incidence Ratios (SIRs) for subsequent p
according to radiotherapy and time since first cancer diagno
Bone sarcoma
Time since 1st Radiotherapy No radiother
Cancer diagnosis Obs SIR Obs S
1-4 yrs 34 1.49* 77 1
5-9 yrs 43 2.74* 56 1
10-14 yrs 23 3.23* 34 1
15+ yrs 23 4.35* 24 0
Total 123 2.42* 191 1
*p < 0.05. Obs-observed number of subsequent primary sarcomas. Analysis includes
(excluding bone sarcoma or soft tissue sarcoma, respectively). Follow-up for second
unknown radiotherapy were excluded.joint effect of the two treatments was additive rather
than multiplicative. Most of these studies did not have
large enough sample sizes to investigate the impact of
different types of chemotherapy in detail, but the most
common treatments involved alkylating agents.
Only two studies [6,8] investigated the impact of the ra-
diation dose per fraction. Le Vu et al. [6] found that smal-
ler fractions did decrease the subsequent risk of sarcoma,
but Menu-Branthomme et al. [8] did not find any evidence
that fraction size affected the risk. The patients in these
studies were treated over several decades with a variety of
types of radiotherapy including Cobalt-60, orthovoltage
and brachytherapy. The type of radiotherapy was taken
into account in the estimation of the absorbed dose to the
sarcoma site and was not, therefore, routinely investigated
separately as a risk factor itself.
Adulthood radiotherapy
Although there was no evidence of an association between
radiation dose and bone sarcoma in the one study of adult-
hood exposure with individual dose estimates [10], the
study was relatively small (n = 15). Other studies of high-
dose radiotherapy, despite having less detailed exposure in-
formation do support an association. These include bone
marrow transplant patients exposed to high-dose fractions
of radiation given as a conditioning regimen [13], ankylos-
ing spondylitis patients treated with radiotherapy for this
benign condition [14] and a number of studies using
cancer registry data that have limited information on radio-
therapy, typically just yes/no [15,16].
In adults there is one small study of thirteen bone and
soft tissue sarcomas in women who had radiotherapy for
breast cancer where there was some evidence of a dose–
response relationship [11]. All the cases were exposed
and the sarcomas occurred in on near the radiation field
with the lowest estimated dose to the site of the sarcoma
being 11 Gy. In the early study of cervical cancer patients
(1988), which found no evidence of an increased risk of
bone sarcoma, there was also no evidence of an increasedrimary sarcoma after any 1st cancer in adulthood
sis, SEER 9 1973-2008
Soft tissue sarcoma
apy Radiotherapy No radiotherapy
IR Obs SIR Obs SIR
.32* 135 1.22* 311 1.15*
.24 185 2.22* 271 1.21*
.31 78 2.04* 141 1.06
.94 62 2.20* 159 1.21*
.23* 460 1.77* 882 1.16*
adulthood (age 20–79 years at diagnosis) 1+ year survivors of any 1st cancer
primary bone or soft tissue sarcoma continued to age 85 years. Patients with
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studies, however, do find evidence of increased risks of
soft tissue sarcoma after adulthood radiotherapy, particu-
larly after breast cancer [16-19].
We supplemented these adulthood studies with a sys-
tematic evaluation of second sarcomas after any first
cancer in the US Surveillance, Epidemiology and End
Results (SEER) 9 cancer registries [20]. The key advan-
tages of the SEER registries for evaluating rare second
cancers like sarcoma are the large population with long-
term follow-up and systematic reporting of second can-
cers. In this analysis we included one year survivors
diagnosed with a first cancer age 20–79 years between
1973 and 2008. Patients with a first primary bone or soft
tissue sarcoma were excluded because of the difficulty of
classifying second primary sarcomas. Second sarcomas
were included if they were diagnosed before age 85 years.
We compared the observed number of bone or soft tis-
sue sarcomas with the expected number in the general
population, which was estimated using age and sex spe-
cific incidence rates. Standardized incidence ratios (SIRs)
were then calculated as the observed divided by the
expected number of second sarcomas for patients who
received radiotherapy and those that did not. We report
results for all first cancers combined, as well as by type
of first cancer and also examine patterns of SIRs accord-
ing to age at and time since first cancer diagnosis.
In approximately 1.9 million 1+ year adulthood cancer
survivors there were 314 second bone sarcoma and 1342
second soft tissue sarcomas diagnosed after an average
follow-up of 13 years (Table 2). In general these adult can-
cer survivors had a small but significantly increased risk of
developing a sarcoma in the bone or soft tissue compared
to the general population even if they did not receive
radiotherapy (SIR= 1.23 for bone cancer and 1.16 for soft
tissue cancer, p < 0.05). For both types of sarcoma the SIRs
were further elevated for the patients who had received
radiotherapy, and this difference increased with increasing
time since diagnosis of the first cancer (Table 2). By 15+
years after the first cancer diagnosis the SIRs for bone sar-
coma were 4.35 in the radiotherapy group compared to
0.94 in the non-radiotherapy group, and for soft tissueTable 3 Standardized Incidence Ratios for subsequent primar
radiotherapy and age at 1st cancer diagnosis, SEER 9 1973-20
Bone sarcoma
Age at 1st Radiotherapy No radiother
Cancer diagnosis Obs SIR Obs
20-39 yrs 13 4.40* 10
40-59 yrs 42 3.71* 40
60-79 yrs 40 2.60* 57
*p < 0.05. Obs-observed number of subsequent primary sarcomas. SIR-standardized
1+ year survivors of any 1st cancer (excluding bone sarcoma or soft tissue sarcoma,
continued to age 85 years. Patients with unknown radiotherapy were excluded.sarcoma they were 2.20 and 1.21, respectively. The
patients treated at a younger age also had higher SIRs than
those treated at older ages (Table 3). For those diagnosed
before age 40 the SIRs for bone sarcoma were 4.40 for the
radiotherapy group compared to 1.31 in the non-
radiotherapy group, and for soft tissue sarcoma they were
5.32 and 2.25, respectively.
In general for each of the first cancer sites that we exam-
ined the SIRs for subsequent sarcomas were higher in the
patients who were treated with radiotherapy than in the
patients who did not receive radiotherapy (Table 4). There
were some interesting exceptions, however. For example,
there was no evidence of an increased risk of bone sar-
coma after radiotherapy for laryngeal or lung cancer, nor
for prostate or testicular cancer. For soft tissue sarcoma
there was no clear evidence of increased risks after radio-
therapy for laryngeal or brain/CNS cancers. These site-
specific observations warrant further investigation.
Lower-dose radiation exposure (<5 Gy)
The Life Span Study of the Japanese atomic bomb survi-
vors is the most informative study of the relationship be-
tween lower dose radiation exposure (<5 Gy) and
sarcoma. As well as being a large cohort with long-term
follow-up it includes exposure at all ages. The latest report
from this study examined the risk of all sarcomas (includ-
ing those occurring at organ sites) and reported (for the
first time) a significantly increased risk with increasing
dose that was very similar in magnitude to the risk for
other types of solid cancer, but much higher than the esti-
mates from the studies of fractionated high-dose radio-
therapy described above (Excess Relative Risk/Gray (ERR/
Gy) approximately 5 for exposure at age 10) [21]. The
mean dose in this cohort is only about 0.2 Gy. The ERR/
Gy decreased with increasing age at exposure, which is
also the pattern commonly observed for other solid can-
cers and may be due to higher levels of cell turnover at
younger ages. In general there is no evidence of increased
sarcoma risks in patients treated with lower-dose radio-
therapy (<5 Gy) but the statistical power in many of these
studies to detect small excess risks is generally low due to
small numbers [22-24].y sarcoma after any 1st cancer in adulthood according to
08
Soft tissue sarcoma
apy Radiotherapy No radiotherapy
SIR Obs SIR Obs SIR
1.31 52 5.32* 58 2.25*
1.23 129 2.41* 219 1.37*
1.31 177 1.83* 302 1.15*
incidence ratio. Analysis includes adulthood (age 20–79 years at diagnosis)
respectively). Follow-up for second primary bone or soft tissue sarcoma
Table 4 Standardized Incidence Ratios for subsequent primary sarcoma according to type of first cancer and
radiotherapy, SEER 9 1973-2008
Bone sarcoma Soft tissue sarcoma
Radiotherapy No radiotherapy Radiotherapy No radiotherapy
1st cancer type Obs SIR Obs SIR Obs SIR Obs SIR
Oral Cavity and Pharynx 9 7.61* 1 0.49 12 1.95* 8 0.75
Rectum and Anus 6 5.15* 6 1.77 12 1.82 18 0.96
Larynx 2 1.62 2 3.80 6 0.87 3 1.06
Lung and Bronchus 0 0.00 4 1.48 12 3.44* 19 1.30
Female Breast 21 2.59* 21 1.28 104 2.67* 101 1.29*
Cervix Uteri 6 6.62* 1 0.71 10 2.38* 6 1.04
Corpus Uteri 12 3.96* 3 0.62 27 1.89* 29 1.25
Ovary 3 13.99* 2 1.45 6 6.25* 9 1.44
Prostate 8 1.09 19 1.38 89 1.69* 97 1.05
Testis 0 0.00 0 0.00 9 2.60* 8 2.78*
Brain and CNS 3 10.47* 0 0.00 4 3.66* 3 3.44
Thyroid 4 4.12* 2 0.91 11 2.63* 10 1.04
Hodgkin Lymphoma 3 4.28 3 6.37* 22 8.71* 7 3.72*
Non-Hodgkin Lymphoma 10 9.00 7 2.92* 11 1.96 17 1.36
Leukemia 1 17.60 5 3.09* 1 4.17 10 1.16
*p < 0.05. Obs-observed number of subsequent primary sarcomas. SIR-standardized incidence ratio. Analysis includes adulthood (age 20–79 years at diagnosis) 1+
year survivors of the specified 1st cancer type. Follow-up for second primary bone or soft tissue sarcoma continued to age 85 years. Patients with unknown
radiotherapy were excluded.
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There is extensive evidence that high-dose exposure to
radionuclides results in radiation-induced bone sarcomas.
Key studies include the follow-up of radium dial painters
[25], cohorts of patients treated with 224-radium for be-
nign conditions such as bone tuberculosis [26], and a
study of nuclear workers at the Russian Mayak facility
who were exposed to high-doses of plutonium, which con-
centrates in the bone [27]. There is also evidence that in-
ternal radiation exposure induces soft tissue sarcomas
from long-term follow-up of patients treated with thoro-
trast [28]. As mentioned above these studies have previ-
ously been reviewed extensively [3].
Genetic susceptibility
Sarcoma development is not only influenced by dose
related radiation exposure, but also by genetic susceptibil-
ity. Several rare familial genetic syndromes, including fa-
milial gastrointestinal stromal tumor syndrome (GIST),
Li-Fraumeni syndrome, retinoblastoma, Werner syndrome,
Neurofibromatosis Type 1, Costello Syndrome, and Nijmegen
breakage syndrome are associated with increased risk of
bone or soft tissue sarcoma, along with multiple other
tumors [29-31]. The question of whether individuals with
these heritable syndromes are more susceptible to the
effects of ionizing radiation than normal individuals is of
interest, particularly in the context of high doses ofradiotherapy. As early as the 1970’s, a marked increase in
radiosensitivity was noted in clinical reports and cell-based
studies of Ataxia Telangiectasia (A-T), a familial syndrome
with a predisposition to develop lymphomas and leukemia
[32,33]. For sarcoma-related syndromes, however, strong
evidence for radiosensitivity has only been observed for
Nijmegen breakage syndrome (NBS), which is primarily
associated with lymphopoetic tumors [34-36]. Significantly
more x-ray induced chromosomal damage has been
observed in NBS lymphocytes and fibroblasts than in nor-
mal cells [36], lymphoblastoid cell lines from NBS patients
show markedly poorer survival following exposure to radi-
ation compared to those from normal individuals [37], and
case-reports of severe adverse reaction to radiation therapy
have been reported in a clinical setting [38]. Possible
increased radiosensitivity has also been reported in cell-
based experiments of Li-Fraumeni syndrome and retino-
blastoma [39,40]. In human studies, although a recent co-
hort study of mortality from subsequent malignancy in
retinoblastoma patients did not detect a significant inter-
action between hereditary status and treatment with
radiotherapy (p= 0.12), a large proportion of the sarcomas
in the irradiated patients were in the radiation field [41]. A
similar finding was observed in a study of Li-Fraumeni
family members in which 50% of the second sarcomas oc-
curred in the radiotherapy field [42]. A study examining
age of onset of osteosarcoma following retinoblastoma also
Berrington de Gonzalez et al. Clinical Sarcoma Research 2012, 2:18 Page 6 of 8
http://www.clinicalsarcomaresearch.com/content/2/1/18suggested that the latency period between radiotherapy and
osteosarcoma is approximately 1.3 year shorter inside than
outside the radiation field [43].
Based on the evidence up to 1998, the International
Commission for Radiation Protection concluded that
given the high risk of spontaneous cancer in familial dis-
orders, doses of radiation in the order of ≤0.1 Gy were
unlikely to impact significantly on life-time cancer risk
in an affected individual [34]. However, this relative risk
could become important at high doses (5 +Gy), such as
those experienced in radiotherapy. Given the paucity of
evidence accumulated since then, particularly in human
studies, these conclusions remain essentially unchanged.
As described in the paragraphs above, a few rare genetic
variants associated with human cancer susceptibility syn-
dromes appear to increase radiosensitivity in individuals
with certain hereditary cancer syndromes. However, these
syndromes affect only a small proportion of the general
population. Very little empirical evidence exists to date
regarding whether common genetic variants confer an
increased risk of radiation-related cancer in general.,
Given that multiple genetic pathways including DNA
damage repair, radiation fibrogenesis, oxidative stress, and
endothelial cell damage have been implicated in studies of
radiosensitivity [44], at least some part of the genetic con-
tribution defining radiation susceptibility is likely to be
polygenic, with elevated risk resulting from the inheritance
of several low penetrance risk alleles (the “common-vari-
ant-common-disease” model). Identifying this variation in
human populations is not straightforward given that stud-
ies would require large sample sizes and high-quality radi-
ation exposure information, with sufficient power to
adequately address variation in demographic and treat-
ment factors. Regardless, studies directed at increasing
understanding of susceptibility to radiotherapy-related
cancers could be important in identifying high-risk indivi-
duals and may lead to clinical benefits if radiation expo-
sures could be reduced in these patients.Radiation Signatures
Given that exposure to ionizing radiation has been long
associated with increased risk of sarcoma [3], there has
been considerable interest in identifying a “radiation signa-
ture” or in other words a genetic expression profile that can
differentiate between radiation-related tumours and spor-
adic tumours. Studies searching for a radiation signature
have generally used some modification of the 1948 Cahan
criteria for classifying sarcomas as radiation-related: the
tumor must be in the irradiated field, histologically different
from the primary cancer, and have a latency period of at
least five years [45]. While satisfying these criteria is likely
to result in a high probability that the sarcoma is radiation-
related, it does not guarantee that it was radiation-induced.Nonetheless, we maintain the terminology “radiation-
induced” and the comparison group of “sporadic sarcomas”
in this article for succinctness.
Early work in search of a radiation signature for sarcoma
used conventional cytogenetic analysis to identify large-
scale chromosomal abnormalities. Two small studies with-
out a comparison group used trypsin-giemsa banding [46]
and comparative genomic hybridization [47] to detect a
variety of large scale abnormalities – however, only the loss
of material on chromosomes X and 13 was observed using
both techniques. More recent studies using polymerase
chain reaction followed by direct sequencing were able to
examine mutations in specific genes: a high rate of TP53
mutation was observed in radiation-induced sarcomas
compared to sporadic sarcomas (88% vs 20%, and 58% vs.
16.8% for two different series) [48,49]. While both studies
focused on sarcoma subsequent to a variety of primary
tumours, 12/36 of cases in the Gonin-Laurent study were
secondary to retinoblastoma, a syndrome caused by muta-
tions in the RB1 gene. The authors later examined the
status of RB1, TP53 and four additional genes involved
in their regulation, and hypothesized that inactivation of
the p53 allele in 12/36 cases was due to irradiation ra-
ther than RB1 loss. They also noted that neither gene
pathway was inactivated in 40% of radiation-induced
tumours, suggesting the presence of further unidentified
pathways involved in radiation carcinogenesis [50]. A re-
cent study by Hadj-Hamou et al. was able to address mul-
tiple biological pathways using an agnostic and generalizable
microarray analysis approach [51]. The authors identified a
signature of 135 genes from a learning/training set of 12
radiation-induced and 12 sporadic sarcomas, and were
able to discriminate radiation-induced from sporadic sar-
comas in an independent set of 36 sarcomas of various
histologies with 96% sensitivity and 62% specificity. Exam-
ination of the gene pathways suggested a particular role
for mitochondrial genes and genes involved in detoxifica-
tion or antioxidant functions, suggesting that mitochon-
drial dysfunction and chronic oxidative stress could be
hallmarks of radiation-induced tumours. While the results
of this study require replication, this approach may be
useful in identifying distinct molecular signatures for
radiation-induced sarcoma, which in turn could provide
clues regarding the molecular etiology of these tumors. It
will be particularly important to test the approach in dif-
ferent settings of radiation dose and dose fractionation,
while taking into account the potential roles of chemo-
therapy and tumor heterogeneity.
Summary
In summary, radiation exposure remains one of the few
established risk factors for both bone and soft tissue sar-
comas. Similar to many other cancers children have the
highest risks of developing a radiation-related sarcoma.
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vivors suggest, for the first time, that the risk is not limited
to high-dose exposures (10 +Gy), but at lower-dose levels
a radiation-related sarcoma would be an extremely rare
event. While there is evidence that individuals with certain
rare familial genetic syndromes predisposing to sarcoma,
particularly Nijmegen Breakage Syndrome, and possibly
Li-Fraumeni syndrome and retinoblastoma, are particu-
larly sensitive to the effects of high dose radiation, it is un-
clear whether this is also true in low-dose settings. Efforts
to limit unnecessary high-dose radiation exposure, par-
ticularly in children, remain important given the high
fatality rates associated with this disease.
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